Literature DB >> 11252048

The death of cost-minimization analysis?

A H Briggs1, B J O'Brien.   

Abstract

Four different types of evaluation methods, cost-benefit analysis (CBA), cost-utility analysis (CUA), cost-effectiveness analysis (CEA) and cost-minimization analysis (CMA), are usually distinguished. In this note, we pronounce the (near) death of CMA by showing the rare circumstances under which CMA is an appropriate method of analysis. We argue that it is inappropriate for separate and sequential hypothesis tests on differences in effects and costs to determine whether incremental cost-effectiveness (or cost-utility) should be estimated. We further argue that the analytic focus should be on the estimation of the joint density of cost and effect differences, the quantification of uncertainty surrounding the incremental cost-effectiveness ratio and the presentation of such data as cost-effectiveness acceptability curves. Two examples from recently published CEA are employed to illustrate the issues. The first shows a situation where analysts might be tempted (inappropriately) to employ CMA rather than CEA. The second illustrates one of the rare circumstances in which CMA may be justified as a legitimate form of analysis. Copyright 2001 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2001        PMID: 11252048     DOI: 10.1002/hec.584

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  98 in total

1.  An introduction to economic evaluation.

Authors:  S Goodacre; C McCabe
Journal:  Emerg Med J       Date:  2002-05       Impact factor: 2.740

Review 2.  Economic evaluations: a new avenue of outcome assessment in spinal disorders.

Authors:  Nicole van der Roer; Norbert Boos; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

3.  The impact of home hospitalization on healthcare costs of exacerbations in COPD patients.

Authors:  Jaume Puig-Junoy; Alejandro Casas; Jaume Font-Planells; Joan Escarrabill; Carme Hernández; Jordi Alonso; Eva Farrero; Gemma Vilagut; Josep Roca
Journal:  Eur J Health Econ       Date:  2007-01-13

4.  Economic evaluation of nurse practitioners versus GPs in treating common conditions.

Authors:  Angelique T M Dierick-van Daele; Lotte M G Steuten; Job F M Metsemakers; Emmy W C C Derckx; Cor Spreeuwenberg; Hubertus J M Vrijhoef
Journal:  Br J Gen Pract       Date:  2010-01       Impact factor: 5.386

5.  In Brief: cost-effectiveness analyses in orthopaedics.

Authors:  Patrick Vavken; Thomas Bianchi
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

Review 6.  Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy.

Authors:  Anthony J Hatswell; Nick Freemantle; Gianluca Baio
Journal:  Pharmacoeconomics       Date:  2017-02       Impact factor: 4.981

7.  Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancer.

Authors:  Silas C Martin; Dennis D Gagnon; Lucy Zhang; Carsten Bokemeyer; Marinus Van Marwijk Kooy; Ben van Hout
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

8.  A randomised controlled crossover trial of nurse practitioner versus doctor led outpatient care in a bronchiectasis clinic.

Authors:  L D Sharples; J Edmunds; D Bilton; W Hollingworth; N Caine; M Keogan; A Exley
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

9.  Cost-effectiveness of an intervention to reduce emergency re-admissions to hospital among older patients.

Authors:  Nicholas Graves; Mary Courtney; Helen Edwards; Anne Chang; Anthony Parker; Kathleen Finlayson
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

10.  Cost-effectiveness of postural exercise therapy versus physiotherapy in computer screen-workers with early non-specific work-related upper limb disorders (WRULD); a randomized controlled trial.

Authors:  Marjon D van Eijsden; Sylvia A Gerhards; Rob A de Bie; Johan L Severens
Journal:  Trials       Date:  2009-11-17       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.